Skip to main content
Year archive

Can-Fite BioPharma Ltd. — 2020 filings

All 315 regulatory filings released by Can-Fite BioPharma Ltd. (CANF) in 2020, sourced directly from the official regulator.

315 Filings
2020 Period
2020 filings (315)
Filing Released Lang
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-12-15 English
Can-Fite receives Israel Ministry of Health approval to conduct research with cannabinoids in cancer, inflammation and obesity at the company discovery labs
Regulatory Filings
2020-12-15 English
Can-Fite receives Israel Ministry of Health approval to conduct research with cannabinoids in cancer, inflammation and obesity at the company discovery labs
Report Publication Announcement
2020-12-15 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-12-14 English
reports on progress with its Namodenoson NASH program
Regulatory Filings
2020-12-14 English
reports on progress with its Namodenoson NASH program
Report Publication Announcement
2020-12-14 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-12-09 English
Results of Annual General Meeting of Shareholders that was held on December 9, 2020
AGM Information
2020-12-09 English
Results of Annual General Meeting of Shareholders that was held on December 9, 2020
AGM Information
2020-12-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-12-02 English
Postponement of meeting due to lack of quorum, will be reconvened on Wednesday, December 9, 2020 at 12:00p.m., Israel time
Regulatory Filings
2020-12-02 English
Postponement of meeting due to lack of quorum, will be reconvened on Wednesday, December 9, 2020 at 12:00p.m., Israel time
Report Publication Announcement
2020-12-02 English
Postponement of meeting due to lack of quorum, will be reconvened on Wednesday, December 9, 2020 at 12:00p.m., Israel time
AGM Information
2020-12-02 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-11-30 English
Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update
Interim / Quarterly Report 9M 2020
2020-11-30 English
Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update
Report Publication Announcement
2020-11-30 English
REPORT OF FOREIGN PRIVATE
Regulatory Filings
2020-11-24 English
Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD)
Regulatory Filings
2020-11-24 English
Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD)
Report Publication Announcement
2020-11-24 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-11-16 English
Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference
Regulatory Filings
2020-11-16 English
Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference
Report Publication Announcement
2020-11-16 English
F-6EF
Regulatory Filings
2020-11-06 English
Bank Of New York Mellon filed a Form F-6 with the SEC
Capital/Financing Update
2020-11-06 English
Bank Of New York Mellon filed a Form F-6 with the SEC
Report Publication Announcement
2020-11-06 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-10-28 English
NOTICE OF 2020 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 2, 2020
Proxy Solicitation & Information Statement
2020-10-28 English
NOTICE OF 2020 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 2, 2020
AGM Information
2020-10-28 English
NOTICE OF 2020 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 2, 2020
AGM Information
2020-10-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-10-13 English
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020
Regulatory Filings
2020-10-13 English
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020
Regulatory Filings
2020-10-13 English
Regulatory Filings 2020
Regulatory Filings
2020-10-13 English
Regulatory Filings 2020
Regulatory Filings
2020-10-07 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-10-06 English
Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis
Regulatory Filings
2020-10-06 English
Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis
Regulatory Filings
2020-10-06 English
Regulatory Filings 2020
Regulatory Filings
2020-10-02 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-09-30 English
Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference
Regulatory Filings
2020-09-30 English
Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference
Regulatory Filings
2020-09-30 English
REGISTRATION STATEMENT
Regulatory Filings
2020-09-25 English
Shelf registration Statement on Form F-3
Regulatory Filings
2020-09-25 English
Shelf registration Statement on Form F-3
Report Publication Announcement
2020-09-25 English
Regulatory Filings 2020
Regulatory Filings
2020-09-08 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-08-31 English
FDA has issued a “safe to proceed” notice for Can-Fite’s IND application for a Phase II study of its lead drug candidate Piclidenoson in the treatment of COVID-19
Regulatory Filings
2020-08-31 English
FDA has issued a “safe to proceed” notice for Can-Fite’s IND application for a Phase II study of its lead drug candidate Piclidenoson in the treatment of COVID-19
Regulatory Filings
2020-08-31 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1
Regulatory Filings
2020-08-28 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT
Capital/Financing Update
2020-08-28 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT
Regulatory Filings
2020-08-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-08-27 English
financial results for the six months ended June 30, 2020 and updates on its drug development programs
Interim / Quarterly Report H1 2020
2020-08-27 English
financial results for the six months ended June 30, 2020 and updates on its drug development programs
Report Publication Announcement H1 2020
2020-08-27 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-08-25 English
Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH
Regulatory Filings
2020-08-25 English
Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH
Report Publication Announcement
2020-08-25 English
FORM 6-K
Regulatory Filings
2020-08-12 English
Results of Special General Meeting of the company's shareholders
Regulatory Filings
2020-08-12 English
Results of Special General Meeting of the company's shareholders
AGM Information
2020-08-12 English
Special meeting convened to August 5, 2020 adjourned to August 12 due to the lack of a legal quorum
Director's Dealing
2020-08-05 Hebrew (modern)
Special meeting convened to August 5, 2020 adjourned to August 12 due to the lack of a legal quorum
Proxy Solicitation & Information Statement
2020-08-05 English
Special meeting convened to August 5, 2020 adjourned to August 12 due to the lack of a legal quorum
Proxy Solicitation & Information Statement
2020-08-05 English
Special meeting convened to August 5, 2020 adjourned to August 12 due to the lack of a legal quorum
Proxy Solicitation & Information Statement
2020-08-05 English
Special meeting convened to August 5, 2020 adjourned to August 12 due to the lack of a legal quorum
Regulatory Filings
2020-08-05 English
Special meeting convened to August 5, 2020 adjourned to August 12 due to the lack of a legal quorum
AGM Information
2020-08-05 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-08-05 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-07-27 English
Can-Fite submits Investigational New Drug application to U.S. FDA for COVID-19 phase II study
Regulatory Filings
2020-07-27 English
Can-Fite submits Investigational New Drug application to U.S. FDA for COVID-19 phase II study
Regulatory Filings
2020-07-27 English
Regulatory Filings 2020
Regulatory Filings
2020-07-27 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2020-07-24 English
424B3-prospectus 96,736,980 Ordinary Shares represented by 3,224,566 American Depositary Shares
Share Issue/Capital Change
2020-07-24 English
424B3-prospectus 96,736,980 Ordinary Shares represented by 3,224,566 American Depositary Shares
Report Publication Announcement
2020-07-24 English
Regulatory Filings 2020
Regulatory Filings
2020-07-22 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-07-20 English
Completes development of an assay to identify clinically active cannabis derived compounds
Regulatory Filings
2020-07-20 English
Completes development of an assay to identify clinically active cannabis derived compounds
Regulatory Filings
2020-07-20 English
Regulatory Filings 2020
Regulatory Filings
2020-07-18 English
Regulatory Filings 2020
Regulatory Filings
2020-07-17 English
FORM D -Notice of Exempt Offering of Securities
Regulatory Filings
2020-07-17 English
FORM D -Notice of Exempt Offering of Securities
Regulatory Filings
2020-07-17 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-07-15 English
amended its Phase II COVID-19 study protocol based on inputs from the U.S. Food and Drug Administration (FDA) and its Pre-Investigational New Drug (IND) fling
Regulatory Filings
2020-07-15 English
amended its Phase II COVID-19 study protocol based on inputs from the U.S. Food and Drug Administration (FDA) and its Pre-Investigational New Drug (IND) fling
Regulatory Filings
2020-07-15 English
REGISTRATION STATEMENT
Regulatory Filings
2020-07-10 English
Resale registration statement on form F-1
Capital/Financing Update
2020-07-10 English
Resale registration statement on form F-1
Capital/Financing Update
2020-07-10 English
424B Prospectus Supplement
Capital/Financing Update
2020-07-08 English
424B Prospectus Supplement
Report Publication Announcement
2020-07-08 English
6-K Offering Documents
Regulatory Filings
2020-07-08 English
6-K Offering Documents
Report Publication Announcement
2020-07-08 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2020-07-08 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-07-08 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-07-06 English
announced it has entered into definitive agreements with certain institutional and accredited investors to receive gross proceeds of approximately $3.4 million
Regulatory Filings
2020-07-06 English
announced it has entered into definitive agreements with certain institutional and accredited investors to receive gross proceeds of approximately $3.4 million
Capital/Financing Update
2020-07-06 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-06-30 English
Final data analysis from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH) has been com
Regulatory Filings
2020-06-30 English
Final data analysis from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH) has been com
Report Publication Announcement
2020-06-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-06-30 English
6K:NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 5, 2020
Proxy Solicitation & Information Statement
2020-06-29 English
6K:NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 5, 2020
Report Publication Announcement
2020-06-29 English
Immediate Report of Meeting
Director's Dealing
2020-06-29 Hebrew (modern)
Immediate Report of Meeting
Proxy Solicitation & Information Statement
2020-06-29 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement
2020-06-29 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement
2020-06-29 English
Regulatory Filings 2020
Regulatory Filings
2020-06-19 English
FORM D -Notice of Exempt Offering of Securities
Regulatory Filings
2020-06-19 English
FORM D -Notice of Exempt Offering of Securities
Report Publication Announcement
2020-06-19 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-06-19 English
SC 13G
Major Shareholding Notification
2020-06-19 English
424B5 Prospectus Supplement
Capital/Financing Update
2020-06-12 English
424B5 Prospectus Supplement
Report Publication Announcement
2020-06-12 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2020-06-12 English
SECURITIES PURCHASE AGREEMENT
Regulatory Filings
2020-06-12 English
SECURITIES PURCHASE AGREEMENT
Report Publication Announcement
2020-06-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-06-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-06-10 English
Can-Fite announced it has entered into definitive agreements with certain institutional and accredited investors to receive gross proceeds of approximately $8,000,000
Regulatory Filings
2020-06-10 English
Can-Fite announced it has entered into definitive agreements with certain institutional and accredited investors to receive gross proceeds of approximately $8,000,000
Capital/Financing Update
2020-06-10 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-06-09 English
Following Pre-IND guidance from FDA Can-Fite to advance Piclidenoson into phase II COVID-19 trial in the U.S.
Regulatory Filings
2020-06-09 English
Following Pre-IND guidance from FDA Can-Fite to advance Piclidenoson into phase II COVID-19 trial in the U.S.
Report Publication Announcement
2020-06-09 English
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer
Regulatory Filings
2020-06-04 English
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer
Report Publication Announcement
2020-06-04 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-06-04 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2020-06-01 English
Amendment to 424B3 Prospectus DATED 7.4.20
Regulatory Filings
2020-06-01 English
Amendment to 424B3 Prospectus DATED 7.4.20
Regulatory Filings
2020-06-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-06-01 English
Reissued Financial Statements under US GAPP for year ended 2019 and Related Financial Data and Financial Statements for first quarter ended March 31, 2020 and Clinical Updates
Annual Report FY 2019
2020-06-01 English
Reissued Financial Statements under US GAPP for year ended 2019 and Related Financial Data and Financial Statements for first quarter ended March 31, 2020 and Clinical Updates
Report Publication Announcement
2020-06-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-05-21 English
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
Regulatory Filings
2020-05-21 English
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
Report Publication Announcement
2020-05-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-05-18 English
Additional finding from Phase II NASH study: 25 mg dose of Namodenoson significantly reduced liver fat and fibrosis
Regulatory Filings
2020-05-18 English
Additional finding from Phase II NASH study: 25 mg dose of Namodenoson significantly reduced liver fat and fibrosis
Report Publication Announcement
2020-05-18 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-05-15 English
Can-Fite BioPharma Ltd. has filed an IND meeting request with the FDA for its drug candidate Piclidenoson in the treatment of COVID-19 patients with moderate-to-severe symptoms.
Regulatory Filings
2020-05-15 English
Can-Fite BioPharma Ltd. has filed an IND meeting request with the FDA for its drug candidate Piclidenoson in the treatment of COVID-19 patients with moderate-to-severe symptoms.
Report Publication Announcement
2020-05-15 English
Change in Association Documents
Regulatory Filings
2020-04-28 English
Change in Association Documents
Report Publication Announcement
2020-04-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-04-28 English
The special meeting of shareholders approved the proposal brought before the Company’s shareholders at the meeting, in accordance with the majority required for the proposal.
Regulatory Filings
2020-04-28 English
The special meeting of shareholders approved the proposal brought before the Company’s shareholders at the meeting, in accordance with the majority required for the proposal.
Declaration of Voting Results & Voting Rights Announcements
2020-04-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-04-27 English
I the Special Meeting will be reconvened on Tuesday, April 28, 2020 at 10:00 a.m. (Israel time)
Proxy Solicitation & Information Statement
2020-04-27 English
I the Special Meeting will be reconvened on Tuesday, April 28, 2020 at 10:00 a.m. (Israel time)
Proxy Solicitation & Information Statement
2020-04-27 English
I the Special Meeting will be reconvened on Tuesday, April 28, 2020 at 10:00 a.m. (Israel time)
AGM Information
2020-04-27 English
the Special Meeting will be reconvened on Tuesday, April 28, 2020 at 10:00 a.m. (Israel time)
Regulatory Filings
2020-04-27 English
the Special Meeting will be reconvened on Tuesday, April 28, 2020 at 10:00 a.m. (Israel time)
AGM Information
2020-04-27 English
FORM 6-K
Regulatory Filings
2020-04-21 English
holding an adjourned meeting on 28.4.20
Proxy Solicitation & Information Statement
2020-04-21 English
holding an adjourned meeting on 28.4.20
Proxy Solicitation & Information Statement
2020-04-21 English
holding an adjourned meeting on 28.4.20
AGM Information
2020-04-21 English
Special Meeting of Shareholders will be reconvened on Tuesday, April 28, 2020
Regulatory Filings
2020-04-21 English
Special Meeting of Shareholders will be reconvened on Tuesday, April 28, 2020
AGM Information
2020-04-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-04-13 English
Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
Regulatory Filings
2020-04-13 English
Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
Report Publication Announcement
2020-04-13 English
Regulatory Filings 2020
Regulatory Filings
2020-04-08 English
Regulatory Filings 2020
Regulatory Filings
2020-04-08 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2020-04-07 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2020-04-07 English
424B3 Prospectus Supplement no. 1
Regulatory Filings
2020-04-07 English
424B3 Prospectus Supplement no. 1
Report Publication Announcement
2020-04-07 English
424B3 Prospectus for ordinary shares issuable upon the exercise of warrants
Share Issue/Capital Change
2020-04-07 English
424B3 Prospectus for ordinary shares issuable upon the exercise of warrants
Regulatory Filings
2020-04-07 English
Regulatory Filings 2020
Regulatory Filings
2020-04-07 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-04-07 English
Can-Fite BioPharma announcing that its Phase II exploratory NAFLD/NASH study with Namodenoson
Regulatory Filings
2020-04-07 English
Can-Fite BioPharma announcing that its Phase II exploratory NAFLD/NASH study with Namodenoson
Report Publication Announcement
2020-04-07 English
Regulatory Filings 2020
Regulatory Filings
2020-04-06 English
Post-effective amendment to Form F-1
Regulatory Filings
2020-04-06 English
Post-effective amendment to Form F-1
Regulatory Filings
2020-04-06 English
Regulatory Filings 2020
Regulatory Filings
2020-04-06 English
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1
Regulatory Filings
2020-04-06 English
Special Meeting of Shareholders on 21.4.20 -Amendment of the record date
Proxy Solicitation & Information Statement
2020-04-02 English
Special Meeting of Shareholders on 21.4.20 -Amendment of the record date
AGM Information
2020-04-02 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-04-02 English
Regulatory Filings 2020
Regulatory Filings
2020-04-02 English
6K-NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 21, 2020
Proxy Solicitation & Information Statement
2020-04-01 English
6K-NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 21, 2020
Report Publication Announcement
2020-04-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-04-01 English
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 21, 2020
Proxy Solicitation & Information Statement
2020-04-01 English
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 21, 2020
Proxy Solicitation & Information Statement
2020-04-01 English
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 21, 2020
Proxy Solicitation & Information Statement
2020-04-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-03-30 English
Can-Fite implements interim analysis for its Phase III Psoriasis trial with data expected Q4 2020
Regulatory Filings
2020-03-30 English
Can-Fite implements interim analysis for its Phase III Psoriasis trial with data expected Q4 2020
Report Publication Announcement
2020-03-30 English
Resale registration Statement on Form F-1
Capital/Financing Update
2020-03-27 English
Resale registration Statement on Form F-1
Report Publication Announcement
2020-03-27 English
REGISTRATION STATEMENT
Regulatory Filings
2020-03-27 English
Post-effective amendment to Form F-1
Capital/Financing Update
2020-03-27 English
Post-effective amendment to Form F-1
Report Publication Announcement
2020-03-27 English
Form 20-F For the fiscal year ended December 31, 2019
Annual Report FY 2019
2020-03-27 English
Form 20-F For the fiscal year ended December 31, 2019
Report Publication Announcement
2020-03-27 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1
Regulatory Filings
2020-03-27 English
ANNUAL REPORT
Annual Report FY 2019
2020-03-27 English
FORM 6-K
Regulatory Filings
2020-03-27 English
reports 2019 financial results & provides clinical development update
Earnings Release FY 2019
2020-03-27 English
reports 2019 financial results & provides clinical development update
Report Publication Announcement
2020-03-27 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-03-23 English
Piclidenoson is submitted for compassionate use treatment for coronavirus patients in Israel
Regulatory Filings
2020-03-23 English
Piclidenoson is submitted for compassionate use treatment for coronavirus patients in Israel
Report Publication Announcement
2020-03-23 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-03-18 English
digital Bio-Europe Spring Partnering Conference; Looks to partner on co-development of Piclidenoson for coronavirus treatment
Regulatory Filings
2020-03-18 English
digital Bio-Europe Spring Partnering Conference; Looks to partner on co-development of Piclidenoson for coronavirus treatment
Report Publication Announcement
2020-03-18 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-03-16 English
Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson
Regulatory Filings
2020-03-16 English
Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson
Report Publication Announcement
2020-03-16 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-03-13 English
Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University
Regulatory Filings
2020-03-13 English
Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University
Report Publication Announcement
2020-03-13 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-03-11 English
New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD
Regulatory Filings
2020-03-11 English
New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD
Report Publication Announcement
2020-03-11 English
Can-Fite BioPharma Ltd. has posted to its website an updated corporate presentation
Investor Presentation
2020-03-09 English
Can-Fite BioPharma Ltd. has posted to its website an updated corporate presentation
Report Publication Announcement
2020-03-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-03-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-03-05 English
Other Report or Announcement
Regulatory Filings
2020-03-05 English
Other Report or Announcement
Report Publication Announcement
2020-03-05 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-03-03 English
Can-Fite is filing Drug Safety Update Report showing positive safety results from phase ii and phase iii studies of Namodenoson and Piclidenoson
Regulatory Filings
2020-03-03 English
Can-Fite is filing Drug Safety Update Report showing positive safety results from phase ii and phase iii studies of Namodenoson and Piclidenoson
Report Publication Announcement
2020-03-03 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-02-27 English
Demonstrate CBD’s Robust Anti-Cancer Effect Against Liver Cancer; Can Fite and Univo Pharmaceuticals Expand Collaboration Agreement
Regulatory Filings
2020-02-27 English
Demonstrate CBD’s Robust Anti-Cancer Effect Against Liver Cancer; Can Fite and Univo Pharmaceuticals Expand Collaboration Agreement
Report Publication Announcement
2020-02-27 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-02-24 English
6k:Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications
Regulatory Filings
2020-02-24 English
6k:Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications
Report Publication Announcement
2020-02-24 English
CURRENT REPORT OF FOREIGN ISSUER
Regulatory Filings
2020-02-20 English
A Special General Meeting of Shareholders of Can-Fite BioPharma Ltd. approved the proposals brought before the Company’s shareholders at the meeting, in accordance with the majority required for each
Declaration of Voting Results & Voting Rights Announcements
2020-02-20 English
A Special General Meeting of Shareholders of Can-Fite BioPharma Ltd. approved the proposals brought before the Company’s shareholders at the meeting, in accordance with the majority required for each
AGM Information
2020-02-20 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-20 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-02-18 English
Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter
Regulatory Filings
2020-02-18 English
Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter
Report Publication Announcement
2020-02-18 English
SC 13G/A
Major Shareholding Notification
2020-02-14 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-02-13 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement
2020-02-13 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement
2020-02-13 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement
2020-02-13 English
announced it has submitted the study’s protocol design and registration plan for its pivotal Phase III liver cancer trial to the European Medicines Agency’s (EMA) Committee for Medicinal...
Regulatory Filings
2020-02-13 English
announced it has submitted the study’s protocol design and registration plan for its pivotal Phase III liver cancer trial to the European Medicines Agency’s (EMA) Committee for Medicinal...
AGM Information
2020-02-13 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-02-13 English
announced today it has submitted the study’s protocol design and registration plan for its pivotal Phase III liver cancer trial to the European Medicines Agency’s (EMA) Committee for Medicinal Product
Regulatory Filings
2020-02-13 English
announced today it has submitted the study’s protocol design and registration plan for its pivotal Phase III liver cancer trial to the European Medicines Agency’s (EMA) Committee for Medicinal Product
Regulatory Filings
2020-02-13 English
Closing of a public offering in the U.S.
Regulatory Filings
2020-02-12 English
Closing of a public offering in the U.S.
Capital/Financing Update
2020-02-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-02-12 English
424B4 Prospectus Supplement
Capital/Financing Update
2020-02-12 English
424B4 Prospectus Supplement
Report Publication Announcement
2020-02-12 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2020-02-12 English
AMENDMENT NO. 1 TO SCHEDULE 13G
Major Shareholding Notification
2020-02-11 English
Regulatory Filings 2020
Regulatory Filings
2020-02-11 English
Announces Pricing of $5 Million Public Offering
Regulatory Filings
2020-02-10 English
Announces Pricing of $5 Million Public Offering
Report Publication Announcement
2020-02-10 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-02-10 English
Amendment to Registration Statement on Form F-1
Capital/Financing Update
2020-02-10 English
Amendment to Registration Statement on Form F-1
Report Publication Announcement
2020-02-10 English
AMENDMENT NO. 2 TO FORM F-1
Regulatory Filings
2020-02-10 English
Regulatory Filings 2020
Regulatory Filings
2020-02-07 English
Regulatory Filings 2020
Regulatory Filings
2020-02-07 English
Regulatory Filings 2020
Regulatory Filings
2020-02-07 English
Regulatory Filings 2020
Regulatory Filings
2020-02-04 English
Regulatory Filings 2020
Regulatory Filings
2020-02-04 English
Amendment to Registration Statement on Form F-1
Capital/Financing Update
2020-02-03 English
Amendment to Registration Statement on Form F-1
Report Publication Announcement
2020-02-03 English
AMENDMENT NO. 1 TO FORM F-1
Regulatory Filings
2020-02-03 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-02-03 English
Can-Fite completes 50% patient enrollment in phase III rheumatoid arthritis study & implements interim analysis
Regulatory Filings
2020-02-03 English
Can-Fite completes 50% patient enrollment in phase III rheumatoid arthritis study & implements interim analysis
Report Publication Announcement
2020-02-03 English
CANF 13G
Major Shareholding Notification
2020-01-31 English
Regulatory Filings 2020
Regulatory Filings
2020-01-30 English
REGISTRATION STATEMENT
Regulatory Filings
2020-01-24 English
Regulatory Filings 2020
Regulatory Filings
2020-01-24 English
FORM D -Notice of Exempt Offering of Securities
Capital/Financing Update
2020-01-24 English
FORM D -Notice of Exempt Offering of Securities
Report Publication Announcement
2020-01-24 English
Registration Statement on Form F-1
Capital/Financing Update
2020-01-24 English
Registration Statement on Form F-1
Report Publication Announcement
2020-01-24 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-01-16 English
Can-Fite and Univo Pharmaceuticals collaboration result in discovery and applied patent for cannabinoid formulations with broad therapeutic effects
Regulatory Filings
2020-01-16 English
Can-Fite and Univo Pharmaceuticals collaboration result in discovery and applied patent for cannabinoid formulations with broad therapeutic effects
Report Publication Announcement
2020-01-16 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2020-01-10 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2020-01-10 English
424B3 F-3 Prospectus Supplement
Regulatory Filings
2020-01-10 English
424B3 F-3 Prospectus Supplement
Regulatory Filings
2020-01-10 English
424B3 Prospectus Supplement
Regulatory Filings
2020-01-10 English
424B3 Prospectus Supplement
Report Publication Announcement
2020-01-10 English
FORM 6-K
Regulatory Filings
2020-01-10 English
Can-Fite BioPharma Ltd. entered into warrant exercise agreements
Regulatory Filings
2020-01-10 English
Can-Fite BioPharma Ltd. entered into warrant exercise agreements
Report Publication Announcement
2020-01-10 English
Can-Fite BioPharma Ltd. announced that it will hold a Special Meeting of Shareholders on February 13, 2020
Proxy Solicitation & Information Statement
2020-01-09 English
Can-Fite BioPharma Ltd. announced that it will hold a Special Meeting of Shareholders on February 13, 2020
AGM Information
2020-01-09 English
Can-Fite BioPharma Ltd. announced that it will hold a Special Meeting of Shareholders on February 13, 2020
AGM Information
2020-01-09 English
Can-Fite BioPharma Ltd. announced that it will hold a Special Meeting of Shareholders on February 13, 2020
Proxy Solicitation & Information Statement
2020-01-09 English
Can-Fite BioPharma Ltd. announced that it will hold a Special Meeting of Shareholders on February 13, 2020
AGM Information
2020-01-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-01-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-01-09 English
Exercise of warrants for cash proceeds of $2.4 million
Regulatory Filings
2020-01-09 English
Exercise of warrants for cash proceeds of $2.4 million
Report Publication Announcement
2020-01-09 English
SABBY 13G-A CANF 1.08.20
Major Shareholding Notification
2020-01-08 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-01-07 English
Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer
Regulatory Filings
2020-01-07 English
Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer
Report Publication Announcement
2020-01-07 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-01-06 English
Can-Fite CEO Issues Letter to Shareholders
Regulatory Filings
2020-01-06 English
Can-Fite CEO Issues Letter to Shareholders
Legal Proceedings Report
2020-01-06 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2020-01-03 English
New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss
Regulatory Filings
2020-01-03 English
New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss
Report Publication Announcement
2020-01-03 English